These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 17616534

  • 21. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients.
    Wang D, Wu WZ, Chen JH, Yang SL, Wang QH, Zeng ZX, Tan JM.
    Transpl Immunol; 2010 Feb; 22(3-4):115-20. PubMed ID: 20036333
    [Abstract] [Full Text] [Related]

  • 22. Serial soluble CD30 measurements as a predictor of kidney graft outcome.
    Halim MA, Al-Otaibi T, Al-Muzairai I, Mansour M, Tawab KA, Awadain WH, Balaha MA, Said T, Nair P, Nampoory MR.
    Transplant Proc; 2010 Apr; 42(3):801-3. PubMed ID: 20430176
    [Abstract] [Full Text] [Related]

  • 23. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation.
    Heinemann FM, Rebmann V, Witzke O, Philipp T, Broelsch CE, Grosse-Wilde H.
    Transplantation; 2007 Mar 27; 83(6):706-11. PubMed ID: 17414702
    [Abstract] [Full Text] [Related]

  • 24. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
    Billing H, Sander A, Süsal C, Ovens J, Feneberg R, Höcker B, Vondrak K, Grenda R, Friman S, Milford DV, Lucan M, Opelz G, Tönshoff B.
    Transpl Int; 2013 Mar 27; 26(3):331-8. PubMed ID: 23279372
    [Abstract] [Full Text] [Related]

  • 25. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes.
    Yang JL, Hao HJ, Zhang B, Liu YX, Chen S, Na YQ.
    Transplant Proc; 2008 Dec 27; 40(10):3381-3. PubMed ID: 19100394
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection.
    Kim KH, Oh EJ, Jung ES, Park YJ, Choi JY, Kim DG, Lee KY, Kang CS.
    Transplant Proc; 2006 Jun 27; 38(5):1429-31. PubMed ID: 16797323
    [Abstract] [Full Text] [Related]

  • 27. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation.
    Hamer R, Roche L, Smillie D, Harmer A, Mitchell D, Molostvov G, Lam FT, Kashi H, Tan LC, Imray C, Fletcher S, Briggs D, Lowe D, Zehnder D, Higgins R.
    Transpl Immunol; 2010 Aug 27; 23(4):161-5. PubMed ID: 20600903
    [Abstract] [Full Text] [Related]

  • 28. Post-transplant monitoring of soluble CD30 level as predictor of graft outcome: a single center experience from China.
    Wang D, Wu W, Yang S, Wang Q, Tan J.
    Transpl Immunol; 2012 Dec 27; 27(4):146-50. PubMed ID: 23079227
    [Abstract] [Full Text] [Related]

  • 29. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC, Campos ÉF, Tedesco-Silva H, Felipe CR, Franco MF, Soares MF, Medina-Pestana JO, Gerbase-Delima M.
    Transpl Immunol; 2013 Dec 27; 29(1-4):34-8. PubMed ID: 23928467
    [Abstract] [Full Text] [Related]

  • 30. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols.
    Hire K, Hering B, Bansal-Pakala P.
    Transpl Immunol; 2010 Aug 27; 23(4):209-14. PubMed ID: 20600901
    [Abstract] [Full Text] [Related]

  • 31. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G, Amirzagar AA, Pourmand G, Mehrsai AR, Taherimahmoudi M, Baradaran N, Nicknam MH, Ebrahimi Rad MR, Saraji A, Asadpoor AA, Moheiydin M, Nikbin B.
    Transplant Proc; 2009 Sep 27; 41(7):2800-4. PubMed ID: 19765439
    [Abstract] [Full Text] [Related]

  • 32. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation.
    Nikaein A, Spiridon C, Hunt J, Rosenthal J, Anderson A, Eichhorn E, Magee M, Dewey T, Mack M.
    Clin Transplant; 2007 Sep 27; 21(6):744-7. PubMed ID: 17988268
    [Abstract] [Full Text] [Related]

  • 33. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM, París SC, Arbeláez M, Cotes JM, Süsal C, Torres Y, García LF.
    Hum Immunol; 2007 Aug 27; 68(8):652-60. PubMed ID: 17678719
    [Abstract] [Full Text] [Related]

  • 34. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
    Shooshtarizadeh T, Mohammadali A, Ossareh S, Ataipour Y.
    Exp Clin Transplant; 2013 Jun 27; 11(3):229-33. PubMed ID: 23477385
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P, Pretagostini R, Arpino A, Tamburro ML, Mengasini S, Lattanzi R, De Simone P, Berloco P, Molajoni ER.
    Transplantation; 2005 May 15; 79(9):1154-6. PubMed ID: 15880060
    [Abstract] [Full Text] [Related]

  • 36. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S, Polakowska E.
    Pediatr Transplant; 2011 Aug 15; 15(5):515-8. PubMed ID: 21672104
    [Abstract] [Full Text] [Related]

  • 37. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.
    Langan LL, D'Orsogna L, Park LP, Hughes TL, Irish A, Luxton G, Witt CS, Christiansen FT.
    Clin Transpl; 2006 Aug 15; ():219-25. PubMed ID: 18365380
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
    Cinti P, Pretagostini R, Arpino A, Tamburro ML, Mengasini S, Lattanzi R, De Simone P, Berloco P, Molajoni ER.
    Transplantation; 2005 Mar 15; 79(5):599-601. PubMed ID: 15753850
    [Abstract] [Full Text] [Related]

  • 39. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft.
    Slavcev A, Honsova E, Lodererova A, Pavlova Y, Sajdlova H, Vitko S, Skibova J, Striz I, Viklicky O.
    Transpl Immunol; 2007 Jul 15; 18(1):22-7. PubMed ID: 17584598
    [Abstract] [Full Text] [Related]

  • 40. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
    Vaidya S, Partlow D, Barnes T, Thomas P, Gugliuzza K.
    Clin Transplant; 2006 Jul 15; 20(4):461-4. PubMed ID: 16842522
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.